Loading...

Estrella Immunopharma, Inc.

ESLAWNASDAQ
HealthcareBiotechnology
$0.05
$0.01(29.18%)

Estrella Immunopharma, Inc. (ESLAW) Company Profile & Overview

Explore Estrella Immunopharma, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Estrella Immunopharma, Inc. (ESLAW) Company Profile & Overview

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

SectorHealthcare
IndustryBiotechnology
CEODr. Cheng Liu Ph.D.

Contact Information

510 318 9098
5858 Horton Street, EmeryVille, CA, 94608

Company Facts

CountryUS
Actively Trading

Frequently Asked Questions